News

Carey & Danis, a law firm, has filed four civil lawsuits on behalf of twenty plaintiffs against Johnson & Johnson and Ortho-McNeil Pharmaceutical (Ortho-McNeil), the makers of the

Peregrine Pharmaceuticals has reported an increase in revenues by 345% to $6.7m for the first quarter of fiscal year 2010 ended July 31, 2009, compared to $1.5m for

Cytopia’s Investigational New Drug Application (IND) for CYT387 has passed the FDA review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders. The

Coughlin Stoia Geller Rudman & Robbins (Coughlin Stoia) has filed a class action lawsuit on behalf of an institutional investor in the US District Court for the District

Upp Technology has reported that it has added significant enhancements to its irms|EM (Emergency Management) software. The new irms|EM product enhancements streamline the order fulfillment and distribution process

OSI Pharmaceuticals has initiated two clinical trials with OSI-906, an oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a phase III, multi-center study that will

China Sky One Medical has finished the required research for two new generic drugs for eye treatment and submitted application to the State Food and Drug Administration (SFDA)

Peplin has signed a merger agreement whereby LEO Pharma will acquire all outstanding securities of Peplin for approximately $287.5m in cash. In addition, LEO will provide Peplin with

Shire has received FDA approval for INTUNIV (guanfacine) extended release tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV,